BPC-157 (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a partial sequence of a protein found in human gastric juice. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed across the published model, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers 100 mcg of material, which keeps the arithmetic clean across the small per-injection steps used with this peptide.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow ramp used in educational protocols, where the daily amount is stepped up every couple of weeks so tolerability can be assessed at each level before increasing.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl or roll gently until fully dissolved. Do not shake; aggressive agitation foams and can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Split-Dose Reference Schedule

Some educational protocols divide the daily total into two smaller injections to spread exposure across the day rather than escalating to a higher single dose. The table below shows the same 600 mcg daily ceiling delivered as two equal portions; the per-day total and volume are unchanged from the standard schedule.

Supplies Needed

• BPC-157 vials (30 mg): at 600 mcg/day one vial supplies ~50 doses; roughly 1 vial for an 8-week run, ~2 vials for 12 weeks, ~2 vials for 16 weeks.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): one bottle covers ~3 vials at 3 mL each, so a single bottle comfortably handles a 16-week run.
• Alcohol swabs: two to three 100-count boxes cover an 8–16 week daily schedule.

Protocol Overview

• Research goal: model tissue-repair, angiogenesis and cytoprotection signalling in injury contexts.
• Schedule: once-daily subcutaneous administration in the published educational model.
• Dose band: 200–600 mcg daily, optionally split AM/PM.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed daily cadence and around the same time for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Some protocols place injections near the area of interest in injury models; others use a standard subcutaneous site — both appear in the literature.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, in dry, dark conditions with minimal moisture exposure, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about four weeks. Because a 30 mg vial yields many doses, consider preparing aliquots if the vial will be sampled daily for an extended period, and avoid repeated freeze–thaw cycles.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact across the vial's long life.
• The small per-dose volumes (0.02–0.06 mL) demand careful measurement on the syringe barrel.
• Document each draw — date, volume, remaining material — for reproducibility.

How BPC-157 Works

BPC-157 corresponds to a 15-amino-acid fragment of a protective protein isolated from gastric juice. In preclinical models it appears to act through the nitric-oxide pathway and to upregulate growth-factor and receptor expression, which together promote angiogenesis (new blood-vessel formation) and collagen deposition at sites of tissue damage. Animal studies have reported accelerated healing across gut, tendon, ligament, muscle and skin injury models, alongside anti-inflammatory and cytoprotective effects. The peptide is notably stable in gastric conditions, which is why early human safety work explored an oral route.

Reported Benefits & Side Effects

Benefits observed in models

• Accelerated repair of gut, tendon, muscle and skin injuries in animal data.
• Anti-inflammatory and cytoprotective activity in preclinical settings.
• Promotion of tendon-to-bone healing and angiogenesis in orthopaedic injury models.
• Good tolerability with no serious adverse events reported in early-phase oral safety studies.

Side effects reported

• Occasional mild injection-site reactions such as redness or itching with subcutaneous administration.
• Long-term human safety and efficacy remain under investigation; robust clinical efficacy data is not yet available.

Supporting Research Context

• Most of the supporting evidence is from rodent injury and ischemia models rather than controlled human trials.
• Adequate protein intake and recovery are standard background controls in tissue-healing study designs.
• Findings from animal repair models do not automatically translate to human outcomes.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then withdraw and apply light pressure.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols